Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 2 2Neuroma, Acoustic 1Neurilemmoma 1Meningioma 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × HDAC-42 × 1 year × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡